Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,322,500 shares in the company, valued at $191,931,400. This represents a 0.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

iRadimed Stock Performance

Shares of NASDAQ:IRMD opened at $84.96 on Thursday. iRadimed Corporation has a 52-week low of $47.48 and a 52-week high of $87.88. The business’s 50 day simple moving average is $73.89 and its two-hundred day simple moving average is $64.46. The firm has a market cap of $1.08 billion, a P/E ratio of 52.44 and a beta of 1.04.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 25th. Shareholders of record on Friday, November 14th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, November 14th. iRadimed’s dividend payout ratio (DPR) is 41.21%.

Wall Street Analyst Weigh In

IRMD has been the subject of a number of research reports. Lake Street Capital reissued a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research note on Monday. Roth Capital set a $90.00 price objective on iRadimed in a research note on Friday, October 31st. Weiss Ratings reissued a “buy (b)” rating on shares of iRadimed in a research note on Friday, October 31st. Finally, Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $87.33.

Institutional Trading of iRadimed

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Global Investments boosted its holdings in iRadimed by 2.7% during the third quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after purchasing an additional 188 shares during the last quarter. Jump Financial LLC lifted its position in shares of iRadimed by 4.9% during the 1st quarter. Jump Financial LLC now owns 4,300 shares of the medical equipment provider’s stock worth $226,000 after buying an additional 200 shares in the last quarter. CWM LLC boosted its stake in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in shares of iRadimed by 78.7% in the 1st quarter. First Horizon Advisors Inc. now owns 513 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 226 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.